Sold as Sulla. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Sulfameter (sold as Sulla), first approved Jul 1, 1966, with 0 new uses approved and 0 published complete response letters.
| Registro Nazionale Sindrome Noonan / National Registry of Noonan SyndromeNoonan Syndrome · Istituto Giannina Gaslini | — | Recruiting | Oct 19, 2026 |
| Frailty in the Elderly Oncological and Oncohematological Patient.Sarcopenia in Elderly, Frailty/Sarcopenia · Azienda Socio Sanitaria Territoriale Ovest Milanese, Ospedale di Legnano | — | Enrolling by invitation | Jun 3, 2026 |
| Estimation of Cardiovascular Risk in Patients With Crohn's Disease and Ulcerative Colitis (PROVACI)Ulcerative Colitis, Myocardial Infarction · IRCCS Policlinico S. Donato | — | Recruiting | Jul 31, 2025 |
| Prospective Evaluation on the Role Exerted by Hormonal Contraceptives on 24-h Blood Pressure. A Prospective Observational StudyCardiovascular System Diseases (&Amp; [Cardiac]) · Ospedale Policlinico San Martino | — | Recruiting | Jul 11, 2025 |
| Study on the Effectiveness of an Emollient Cream Containing Pre and Postbiotic and Niacinamide 4% in the Treatment of Skin Xerosis and Itching in Oncological Patients Treated with Anti-EGFRXerosis Cutis · Societa Italiana di Dermatologia Medica, Chirurgica, Estetica e di Malattie Sessualmente Trasmesse | Not applicable | Recruiting | Mar 11, 2025 |
| Protocollo N 2014 - Benign Prostatic HyperplasiaBenign Prostatic Hyperplasia · IRCCS San Raffaele | — | Recruiting | Dec 26, 2023 |
| Effects of Nutrition on Post Stroke FatigueFatigue, Stroke · Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Not applicable | Recruiting | Feb 15, 2023 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 1, 1966 | SullaNDA 16000 · New molecular entity | Bayer Hlthcare | 13 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA